Press coverage about Glaukos (NYSE:GKOS) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Glaukos earned a news impact score of 0.22 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 46.3474885964692 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Glaukos (NYSE GKOS) opened at $28.47 on Wednesday. Glaukos has a one year low of $23.08 and a one year high of $52.49. The firm has a market cap of $984.08 and a P/E ratio of -949.00.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.06. Glaukos had a negative net margin of 0.64% and a positive return on equity of 3.50%. The business had revenue of $40.41 million for the quarter, compared to analyst estimates of $38.69 million. During the same quarter last year, the firm earned $0.03 EPS. Glaukos’s quarterly revenue was up 36.6% compared to the same quarter last year. equities analysts anticipate that Glaukos will post -0.03 earnings per share for the current year.

Several research analysts recently weighed in on the stock. Cantor Fitzgerald set a $48.00 price objective on shares of Glaukos and gave the stock a “buy” rating in a research note on Wednesday, January 10th. Zacks Investment Research lowered shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Wednesday, September 20th. BMO Capital Markets reissued a “buy” rating on shares of Glaukos in a research note on Monday, December 11th. Finally, Stephens reissued an “overweight” rating and set a $40.00 price objective (down previously from $47.00) on shares of Glaukos in a research note on Monday, November 13th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Glaukos presently has an average rating of “Buy” and a consensus target price of $44.86.

In related news, CFO Joseph E. Gilliam bought 2,100 shares of the company’s stock in a transaction on Wednesday, November 22nd. The shares were purchased at an average cost of $23.84 per share, for a total transaction of $50,064.00. Following the acquisition, the chief financial officer now owns 102,100 shares of the company’s stock, valued at approximately $2,434,064. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 16.40% of the company’s stock.

WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at

About Glaukos

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Stock Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related stocks with our FREE daily email newsletter.